SO-4 Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response

Most cholangiocarcinoma (CCA) patients are diagnosed with advanced disease and are ineligible for surgery. First-line, standard-of-care therapy for patients with advanced/metastatic CCA not amenable to surgery is gemcitabine plus cisplatin. FGFR2 fusions or rearrangements are oncogenic drivers of CCA and are almost exclusive to intrahepatic CCA (iCCA; prevalence, 10–15%). However, the role of this alteration and how it impacts patient response...